P2Y12 is a chemoreceptor for adenosine diphosphate (ADP) that belongs to the Gi class of a group of G protein-coupled (GPCR) purinergic receptors. The P2Y12 receptor is involved in platelet aggregation and is thus a biological target for the treatment of thromboembolisms and other clotting disorders. P2Y12 receptor blocker group of drugs includes clopidogrel, ticlopidine, ticagrelor, prasugrel, cangrelor, and others.
The U.S. P2Y12 inhibitors market is estimated to have around US$ 215.7 Mn in 2021, and is expected to exhibit a CAGR of 3.8% during the forecast period (2021-2028).
Figure 1. U.S. P2Y12 Inhibitors Market Share (%) in Terms of Value, By Drug, 2021
The rising incidence of cardiovascular diseases is expected to drive the market growth during the forecast period.
The rising incidence of cardiovascular diseases in the U.S. is expected to drive the growth of the U.S. P2Y12 Inhibitors market over the forecast period. For instance, according to the data published in Centers for Disease Control and Prevention in September 2021, it is estimated that heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the U.S. Moreover, about 659,000 people in the U.S die from heart disease each year.
|Base Year:||2020||Market Size in 2021:||US$ 215.7 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2021 to 2028|
|Forecast Period 2021 to 2028 CAGR:||3.8%||2028 Value Projection:||US$ 279.6 Mn|
Mylan N.V., Bristol-Myers Squibb, Dr Reddy's Laboratories, Teva Pharmaceuticals USA, Inc., AstraZeneca, Genentech, Eli Lilly and Company, Panacea Biotec, CHIESI USA, Inc., Lupin, Cipla, and Biocon
|Restraints & Challenges:||
Figure 2. U.S. P2Y12 Inhibitors Market Share (%), By Distribution Channel, 2021
Increasing product approvals is expected to drive the market growth during the forecast period.
Key players operating in the market are focusing on product approvals which is expected to drive the market growth over forecast period. For instance, in June 2020, AstraZeneca, a biopharmaceutical company’s, Brilinta (ticagrelor) had been approved in the U.S. to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD), the most common type of heart disease.
U.S. P2Y12 Inhibitors Market– Impact of Coronavirus (COVID-19) Pandemic
The coronavirus (COVID-19) pandemic and lockdown in various countries across the globe has impacted the financial status of businesses in all sectors. Private healthcare sector is one of the sectors, which is majorly impacted by the COVID-19 pandemic. Moreover, coronavirus pandemic has negatively impacted the development, production, and supply of pharmaceutical products and affected growth of the severe oral mucositis medications businesses of various companies, across the regions such as North America, as COVID 19 pandemic has led to unprecedented lockdown in several countries such as the U.S. This lockdown has resulted in closure of industrial establishments, except manufacturing of essential commodities, and disruption in supply chain of the pharmaceutical products. Thus, COVID-19 pandemic has affected the economy in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) by its financial impact on firms and financial markets. Supply chain and manufacturing activities in India, Italy, Spain, the U.K., and the U.S. have been disrupted due to lockdowns implemented by governments in the past few months, while countries such as Brazil, France, Russia, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drug products. Due to severe shortage of medical resources at the front line, only patients diagnosed with serious conditions can be hospitalized. Unfortunately, the pathogenic mechanism of the virus has not been identified completely, though, there is presence of vaccines and drugs manufactured by the companies for prevention and treatment of COVID-19. The COVID-19 pandemic has impacted the global economy and in turn, the U.S. P2Y12 inhibitors market.
U.S. P2Y12 Inhibitors Market: Restraint
The major factors that may hinder growth of the U.S. P2Y12 inhibitors market include potential side effects of drugs. For instance, side effects of P2Y12 inhibitors include diarrhea, itching, nausea, skin rash, and stomach pain. Moreover, ticlopidine may lead to a very low white blood cell count or an immune disorder that destroys platelets. Ticagrelor may cause episodes of shortness of breath.
Major players operating in the U.S. P2Y12 inhibitors market include Mylan N.V., Bristol-Myers Squibb, Dr Reddy's Laboratories, Teva Pharmaceuticals USA, Inc., AstraZeneca, Genentech, Eli Lilly and Company, Panacea Biotec, CHIESI USA, Inc., Lupin, Cipla, and Biocon.
P2Y12 receptor blockers are group of antiplatelet drugs. Antiplatelet are medicines that stop cells in the blood (platelets) from sticking together and forming a clot. A blood clot can lead to a heart attack or stroke. The P2Y12 receptor is a key player in platelet activation and represents an effective pharmacological target for the inhibition of platelet aggregation and prevention of atherothrombotic events. P2Y12 receptor blocker includes clopidogrel, ticlopidine, ticagrelor, prasugrel, and cangrelor drugs
Increasing prevalence of cardiovascular disease is expected to drive the market growth during the forecast period. For instance, according to data published in March 2019 by Florida Department of Health, responsible for the regulation of health practitioners for the preservation of the health, safety, and welfare of the public, stated that heart disease accounts for about two out of 10 deaths in Florida. Moreover, there were 80,402 coronary heart disease hospitalizations (including both angina and myocardial infarction) or an average of 220 coronary heart disease hospitalizations each day in 2018. Increasing government initiative to spread awareness regarding cardiovascular diseases is expected to drive the market growth over the forecast period. For instance, Million Hearts 2022, a national initiative co-led by Centers for Disease Control and Prevention and the Centers for Medicare & Medicaid Services to prevent one million heart attacks and strokes in five years. Moreover, the initiative focuses partner actions on a small set of priorities selected for their impact on heart disease, stroke, and related conditions.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.